

MATTHEW C. MACLEAR (SBN 209228) ANTHONY M. BARNES (SBN 199048) 2 AQUA TERRA AERIS LAW GROUP 828 San Pablo Ave, Suite 115B Albany, CA 94706 Ph: 415-568-5200 4 Email: mcm@atalawgroup.com Attorneys for Plaintiff 6 ENVIRONMENTAL RESEARCH CENTER, INC PETER A. ARHANGELKSY SBN (291325) EMORD & ASSOCIATES, P.C. 2730 South Val Vista Drive, Bldg. 6, Ste. 133 Gilbert, AZ 85295 Ph: (602) 388-8899 10 Email: parhangelsky@emord.com Attorney for Defendants 11 VITALAB CO., INC., SONNE'S ORGANIC FOODS, INC., SPRINGREEN PRODUCTS, INC., 12 and V.E. IRONS, INC. 13 14 15 16 17 18 Plaintiff, 19 20 21 22 23 24

ALAMEDA COUNTY

MAY 2 \$ 2017d

CLERK OF THE SUPERIOR COURT

SUPERIOR COURT OF THE STATE OF CALIFORNIA COUNTY OF ALAMEDA

ENVIRONMENTAL RESEARCH CENTER, INC., a non-profit California corporation,

VITALAB CO., INC., a Missouri corporation, SONNE'S ORGANIC FOODS, INC., a Massachusetts corporation, SPRINGREEN PRODUCTS, INC., a Missouri corporation, and V.E. IRONS, INC., a Massachusetts corporation, and DOES 1-25,

Defendants.

CASE NO. RG17851569

STIPULATED CONSENT JUDGMENT

Health & Safety Code § 25249.5 et seq.

Action Filed: March 3, 2017 Trial Date: None set

INTRODUCTION

25

26

27

1.1 On March 3, 2017, Plaintiff Environmental Research Center, Inc. ("ERC"), a nonprofit corporation, as a private enforcer and in the public interest, initiated this action by filing a

Page I of 17

STIPULATED CONSENT JUDGMENT

Case No. RG17851569

ERC and VITALAB are hereinafter referred to individually as a "Party" or collectively as the "Parties."

- 1.2 ERC is a 501 (c)(3) California non-profit corporation dedicated to, among other causes, helping safeguard the public from health hazards by reducing the use and misuse of hazardous and toxic chemicals, facilitating a safe environment for consumers and employees, and encouraging corporate responsibility.
- 1.3 For purposes of this Consent Judgment, the Parties agree that each defendant is a business entity each of which has employed ten or more persons at all times relevant to this action, and qualifies as a "person in the course of business" within the meaning of Proposition 65. VITALAB manufactures, distributes, and/or sells the Covered Products.
- Notice of Violation (NOV) served on DEFENDANTS VITALAB CO., INC. and SONNE'S ORGANIC FOODS, INC. for the SUBJECT PRODUCTS listed in section 1.1, subdivisions A through E, and the NOV dated December 22, 2016, served on DEFENDANTS VITALAB CO., INC., SPRINGREEN PRODUCTS, INC., and V.E. IRONS, INC. for the SUBJECT PRODUCTS listed in section 1.1, subdivisions F through K. The October 14, 2016 and December 22, 2016 Notices of Violation (collectively "Notices") were also served on the California Attorney General, other public enforcers, and VITALAB. True and correct copies of the 60-Day Notices are attached hereto as Exhibits A and B respectively and each is incorporated herein by reference. More than 60 days have passed since the Notices were served on the Attorney General, public enforcers, and VITALAB and no designated governmental entity has filed a complaint against VITALAB with regard to the Covered Products or the alleged violations.
- 1.5 ERC's Notices and Complaint allege that use of the Covered Products exposes persons in California to lead without first providing clear and reasonable warnings in violation of California Health and Safety Code section 25249.6. VITALAB denies all material allegations contained in the Notices and Complaint.

- 1.6 The Parties have entered into this Consent Judgment in order to settle, compromise, and resolve disputed claims and thus avoid prolonged and costly litigation.

 Nothing in this Consent Judgment nor compliance with this Consent Judgment shall constitute or be construed as an admission by any of the Parties or by any of their respective officers, directors, shareholders, employees, agents, parent companies, subsidiaries, divisions, franchisees, licensees, customers, suppliers, distributors, wholesalers, or retailers of any fact, issue of law, or violation of law.
- 1.7 Except as expressly set forth herein, nothing in this Consent Judgment shall prejudice, waive, or impair any right, remedy, argument, or defense the Parties may have in any current or future legal proceeding unrelated to these proceedings.
- 1.8 The Effective Date of this Consent Judgment is the date on which it is entered as a Judgment by this Court.

2. JURISDICTION AND VENUE

For purposes of this Consent Judgment and any further court action that may become necessary to enforce this Consent Judgment, the Parties stipulate that this Court has subject matter jurisdiction over the allegations of violations contained in the Complaint, personal jurisdiction over VITALAB as to the acts alleged in the Complaint, that venue is proper in Alameda County, and that this Court has jurisdiction to enter this Consent Judgment as a full and final resolution of all claims up through and including the Effective Date which were or could have been asserted in this action based on the facts alleged in the Notices and Complaint.

3. INJUNCTIVE RELIEF, REFORMULATION, TESTING AND WARNINGS

- 3.1 Beginning on the Effective Date, VITALAB shall be permanently enjoined from manufacturing for sale in the State of California, "Distributing into the State of California", or directly selling in the State of California, any Covered Products which exposes a person to a "Daily Lead Exposure Level" of more than 0.5 micrograms of lead per day unless it meets the warning requirements under Section 3.2.
- 3.1.1 As used in this Consent Judgment, the term "Distributing into the State of California" shall mean to directly ship a Covered Product into California for sale in

California or to sell a Covered Product to a distributor that VITALAB knows or has reason to know will sell the Covered Product in California.

3.1.2 For purposes of this Consent Judgment, the "Daily Lead Exposure Level" shall be measured in micrograms, and shall be calculated using the following formula: micrograms of lead per gram of product, multiplied by grams of product per serving of the product (using the largest serving size appearing on the product label), multiplied by servings of the product per day (using the largest number of servings in a recommended dosage appearing on the product label), which equals micrograms of lead exposure per day.

3.2 Clear and Reasonable Warnings

If VITALAB is required to provide a warning pursuant to Section 3.1, one or more of the following warnings must be utilized ("Warning"):

- A. WARNING: Consuming this product can expose you to chemicals including lead which is [are] known to the State of California to cause [cancer and] birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov/food.
- B. [Warning symbol required in Section 25603(a)(1) of Title 27, California Code of Regulations]WARNING: [Cancer and] Reproductive Harm www.P65Warnings.ca.gov/food.

VITALAB shall use the phrase "cancer and" in the Warning only if the "Daily Lead Exposure Level" is greater than 15 micrograms of lead as determined pursuant to the quality control methodology set forth in Section 3.4.

The Warning shall be securely affixed to or printed upon the container or label of each Covered Product. In addition, for any Covered Product sold over the internet, the Warning shall appear on the checkout page when a California delivery address is indicated for any purchase of any Covered Product. An asterisk or other identifying method must be utilized to identify which products on the checkout page are subject to the Warning.

The Warning shall be at least the same size as the largest of any other health or safety warnings also appearing on its website or on the label or container of VITALAB's product packaging and the word "WARNING" shall be in all capital letters and in bold print. No statements intended to or likely to have the effect of diminishing the impact of, or reducing the

clarity of, the Warning on the average lay person shall accompany the Warning. Further, no statements may accompany the Warning that state or imply that the source of the listed chemical has an impact on or results in a less harmful effect of the listed chemical.

VITALAB must display the above Warning with such conspicuousness, as compared with other words, statements, design of the label, container, or on its website, as applicable, to render the Warning likely to be read and understood by an ordinary individual under customary conditions of purchase or use of the product.

3.3 Reformulated Covered Products

A Reformulated Covered Product is one for which the "Daily Lead Exposure Level" is no greater than 0.5 micrograms of lead per day as determined by the quality control methodology described in Section 3.4.

3.4 Testing and Quality Control Methodology

arrange for lead testing of the Covered Products at least once a year for a minimum of five consecutive years by arranging for testing of five randomly selected samples of each of the Covered Products, in the form intended for sale to the end-user, which VITALAB intends to sell or is manufacturing for sale in California, directly selling to a consumer in California or "Distributing into the State of California." If tests conducted pursuant to this Section demonstrate that no Warning is required for a Covered Product during each of five consecutive years, then the testing requirements of this Section will no longer be required as to that Covered Product. However, if during or after the five-year testing period, VITALAB changes ingredient suppliers for any of the Covered Products and/or reformulates any of the Covered Products, VITALAB shall test that Covered Product annually for at least four (4) consecutive years after such change is made.

3.4.2 For purposes of measuring the "Daily Lead Exposure Level," the highest lead detection result of the five (5) randomly selected samples of the Covered Products will be controlling.

- 3.4.3 All testing pursuant to this Consent Judgment shall be performed using a laboratory method that complies with the performance and quality control factors appropriate for the method used, including limit of detection, qualification, accuracy, and precision that meets the following criteria: Inductively Coupled Plasma-Mass Spectrometry ("ICP-MS") achieving a limit of quantification of less than or equal to 0.010 mg/kg or any other testing method subsequently agreed to in writing by the Parties and approved by the Court through entry of a modified consent judgment.
- 3.4.4 All testing pursuant to this Consent Judgment shall be performed by an independent third party laboratory certified by the California Environmental Laboratory Accreditation Program or an independent third-party laboratory that is registered with the United States Food & Drug Administration.
- 3.4.5 Nothing in this Consent Judgment shall limit VITALAB's ability to conduct, or require that others conduct, additional testing of the Covered Products, including the raw materials used in their manufacture.
- 3.4.6 Within thirty (30) days of ERC's written request, VITALAB shall deliver lab reports obtained pursuant to Section 3.4 to ERC. VITALAB shall retain all test results and documentation for a period of five years from the date of each test.

4. SETTLEMENT PAYMENT

- 4.1 In full satisfaction of all potential civil penalties, additional settlement payments, attorney's fees, and costs, VITALAB shall make a total payment of \$101,000.00 ("Total Settlement Amount") to ERC within 10 days of the Effective Date ("Due Date"). VITALAB shall make this payment by wire transfer to ERC's escrow account, for which ERC will give VITALAB the necessary account information. The Total Settlement Amount shall be apportioned as follows:
- 4.2 \$35,776.33 shall be considered a civil penalty pursuant to California Health and Safety Code section 25249.7(b)(1). ERC shall remit 75% (\$26,832.25) of the civil penalty to the Office of Environmental Health Hazard Assessment ("OEHHA") for deposit in the Safe

Drinking Water and Toxic Enforcement Fund in accordance with California Health and Safety Code section 25249.12(c). ERC will retain the remaining 25% (\$8,944.08) of the civil penalty.

- 4.3 \$4,916.43 shall be distributed to ERC as reimbursement to ERC for reasonable costs incurred in bringing this action.
- \$26,832.20 shall be distributed to ERC as an Additional Settlement Payment ("ASP"), pursuant to California Code of Regulations, title 11, sections 3203, subdivision (d) and 3204. ERC will utilize the ASP for activities that address the same public harm as allegedly caused by VITALAB in this matter. These activities are detailed below and support ERC's overarching goal of reducing and/or eliminating hazardous and toxic chemicals in dietary supplement products in California. ERC's activities have had, and will continue to have, a direct and primary effect within the State of California because California consumers will be benefitted by the reduction and/or elimination of exposure to lead in dietary supplements and/or by providing clear and reasonable warnings to California consumers prior to ingestion of the products.

Based on a review of past years' actual budgets, ERC is providing the following list of activities ERC engages in to protect California consumers through Proposition 65 citizen enforcement, along with a breakdown of how ASP funds will be utilized to facilitate those activities: (1) ENFORCEMENT (65-80%): obtaining, shipping, analyzing, and testing dietary supplement products that may contain lead and are sold to California consumers. This work includes continued monitoring and enforcement of past consent judgments and settlements to ensure companies are in compliance with their obligations thereunder, with a specific focus on those judgments and settlements concerning lead. This work also includes investigation of new companies that ERC does not obtain any recovery through settlement or judgment; (2) VOLUNTARY COMPLIANCE PROGRAM (10-20%): maintaining ERC's Voluntary Compliance Program by acquiring products from companies, developing and maintaining a case file, testing products from these companies, providing the test results and supporting documentation to the companies, and offering guidance in warning or implementing a self-testing program for lead in dietary supplement products; and (3) "GOT LEAD" PROGRAM (up

to 5%): maintaining ERC's "Got Lead?" Program which reduces the numbers of contaminated products that reach California consumers by providing access to free testing for lead in dietary supplement products (Products submitted to the program are screened for ingredients which are suspected to be contaminated, and then may be purchased by ERC, catalogued, sent to a qualified laboratory for testing, and the results shared with the consumer that submitted the product).

ERC shall be fully accountable in that it will maintain adequate records to document and will be able to demonstrate how the ASP funds will be spent and can assure that the funds are being spent only for the proper, designated purposes described in this Consent Judgment. ERC shall provide the Attorney General, within thirty days of any request, copies of documentation demonstrating how such funds have been spent.

- 4.5 \$14,177.50 shall be distributed to Aqua Terra Aeris Law Group as reimbursement of ERC's attorney's fees, while \$19,297.54 shall be distributed to ERC for its in-house legal fees. Except as explicitly provided herein, each Party shall bear its own fees and costs.
- under Section 4 of this Consent Judgment on or before the Due Date, VITALAB shall be deemed to be in material breach of its obligations under this Consent Judgment. ERC shall provide written notice of the delinquency to VITALAB via electronic mail. If VITALAB fails to deliver the Total Settlement Amount within five (5) days from the written notice, the Total Settlement Amount shall accrue interest at the statutory judgment interest rate provided in the California Code of Civil Procedure section 685.010. Additionally, VITALAB agrees to pay ERC's reasonable attorney's fees and costs for any efforts to collect the payment due under this Consent Judgment.

5. MODIFICATION OF CONSENT JUDGMENT

5.1 This Consent Judgment may be modified only as to injunctive terms (i) by written stipulation of the Parties or pursuant to Section 5.4 and (ii) upon entry by the Court of a modified consent judgment.

- VITALAB must provide written notice to ERC of its intent ("Notice of Intent"). If ERC seeks to meet and confer regarding the proposed modification in the Notice of Intent, then ERC must provide written notice to VITALAB within thirty (30) days of receiving the Notice of Intent. If ERC notifies VITALAB in a timely manner of ERC's intent to meet and confer, then the Parties shall meet and confer in good faith as required in this Section. The Parties shall meet in person or via telephone within thirty (30) days of ERC's notification of its intent to meet and confer. Within thirty (30) days of such meeting, if ERC disputes the proposed modification, ERC shall provide to VITALAB a written basis for its position. The Parties shall continue to meet and confer for an additional thirty (30) days in an effort to resolve any remaining disputes. Should it become necessary, the Parties may agree in writing to different deadlines for the meet-and-confer period.
- 5.3 In the event that VITALAB initiates or otherwise requests a modification under Section 5.1, and the meet and confer process leads to a joint motion or application of the Consent Judgment, VITALAB shall reimburse ERC its costs and reasonable attorney's fees for the time spent in the meet-and-confer process and filing and arguing the motion or application.
- 5.4 Where the meet-and-confer process does not lead to a joint motion or application in support of a modification of the Consent Judgment, then either Party may seek judicial relief on its own.

6. RETENTION OF JURISDICTION, ENFORCEMENT OF CONSENT JUDGMENT

- 6.1 This Court shall retain jurisdiction of this matter to enforce, modify, or terminate this Consent Judgment.
- 6.2 If ERC alleges that any Covered Product fails to qualify as a Reformulated Covered Product (for which ERC alleges that no Warning has been provided), then ERC shall inform VITALAB in a reasonably prompt manner of its test results, including information sufficient to permit VITALAB to identify the Covered Products at issue. VITALAB shall, within thirty (30) days following such notice, provide ERC with testing information, from an

 independent third-party laboratory meeting the requirements of Sections 3.4.3 and 3.4.4, demonstrating VITALAB's compliance with the Consent Judgment, if warranted. The Parties shall first attempt to resolve the matter prior to ERC taking any further legal action.

7. APPLICATION OF CONSENT JUDGMENT

This Consent Judgment may apply to, be binding upon, and benefit the Parties and their respective officers, directors, shareholders, employees, agents, parent companies, subsidiaries, divisions, franchisees, licensees, customers (excluding private labelers), distributors, wholesalers, retailers, predecessors, successors, and assigns. This Consent Judgment shall have no application to any Covered Product which is distributed or sold exclusively outside the State of California and which is not used by California consumers.

8. BINDING EFFECT, CLAIMS COVERED AND RELEASED

- 8.1 This Consent Judgment is a full, final, and binding resolution between ERC, on behalf of itself and in the public interest, and VITALAB and its respective officers, directors, shareholders, employees, agents, parent companies, subsidiaries, divisions, suppliers, franchisees, licensees, customers (not including private label customers of VITALAB), distributors, wholesalers, retailers, and all other upstream and downstream entities in the distribution chain of any Covered Product, and the predecessors, successors, and assigns of any of them (collectively, "Released Parties"). ERC hereby fully releases and discharges the Released Parties from any and all claims, actions, causes of action, suits, demands, liabilities, damages, penalties, fees, costs, and expenses asserted, or that could have been asserted from the handling, use, or consumption of the Covered Products, as to any alleged violation of Proposition 65 or its implementing regulations arising from the failure to provide Proposition 65 warnings on the Covered Products regarding lead up to and including the Effective Date.
- 8.2 ERC on its own behalf only, and VITALAB on its own behalf only, further waive and release any and all claims they may have against each other for all actions or statements made or undertaken in the course of seeking or opposing enforcement of Proposition 65 in connection with the Notices and Complaint up through and including the Effective Date, provided, however, that nothing in Section 8 shall affect or limit any Party's right to seek to

enforce the terms of this Consent Judgment.

8.3 It is possible that other claims not known to the Parties, arising out of the facts alleged in the Notices and Complaint, and relating to the Covered Products, will develop or be discovered. ERC on behalf of itself only, and VITALAB on behalf of itself only, acknowledge that this Consent Judgment is expressly intended to cover and include all such claims up through and including the Effective Date, including all rights of action therefore. ERC and VITALAB acknowledge that the claims released in Sections 8.1 and 8.2 above may include unknown claims, and nevertheless waive California Civil Code section 1542 as to any such unknown claims. California Civil Code section 1542 reads as follows:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

ERC on behalf of itself only, and VITALAB on behalf of itself only, acknowledge and understand the significance and consequences of this specific waiver of California Civil Code section 1542.

- 8.4 Compliance with the terms of this Consent Judgment shall be deemed to constitute compliance with Proposition 65 by any releasee regarding alleged exposures to lead in the Covered Products as set forth in the Notices and Complaint.
- 8.5 Nothing in this Consent Judgment is intended to apply to any occupational or environmental exposures arising under Proposition 65, nor shall it apply to any of VITALAB's products other than the Covered Products.

9. SEVERABILITY OF UNENFORCEABLE PROVISIONS

In the event that any of the provisions of this Consent Judgment are held by a court to be unenforceable, the validity of the remaining enforceable provisions shall not be adversely affected.

10. GOVERNING LAW

The terms and conditions of this Consent Judgment shall be governed by and construed in accordance with the laws of the State of California.

the Parties shall use their best efforts to resolve the concern in a timely manner, and if possible prior to the hearing on the motion.

12.3 If this Stipulated Consent Judgment is not approved by the Court, it shall be void and have no force or effect.

13. EXECUTION AND COUNTERPARTS

This Consent Judgment may be executed in counterparts, which taken together shall be deemed to constitute one document. A facsimile or .pdf signature shall be construed to be as valid as the original signature.

14. DRAFTING

The terms of this Consent Judgment have been reviewed by the respective counsel for each Party prior to its signing, and each Party has had an opportunity to fully discuss the terms and conditions with legal counsel. The Parties agree that, in any subsequent interpretation and construction of this Consent Judgment, no inference, assumption, or presumption shall be drawn, and no provision of this Consent Judgment shall be construed against any Party, based on the fact that one of the Parties and/or one of the Parties' legal counsel prepared and/or drafted all or any portion of the Consent Judgment. It is conclusively presumed that all of the Parties participated equally in the preparation and drafting of this Consent Judgment.

15. GOOD FAITH ATTEMPT TO RESOLVE DISPUTES

If a dispute arises with respect to either Party's compliance with the terms of this Consent Judgment entered by the Court, the Parties shall meet and confer in person, by telephone, and/or in writing and endeavor to resolve the dispute in an amicable manner. No action or motion may be filed in the absence of such a good faith attempt to resolve the dispute beforehand.

16. ENFORCEMENT

ERC may, by motion or order to show cause before the Superior Court of Alameda County, enforce the terms and conditions contained in this Consent Judgment. In any action brought by ERC to enforce this Consent Judgment, ERC may seek whatever fines, costs, penalties, or remedies as are provided by law for failure to comply with the Consent Judgment. To the extent the failure to comply with the Consent Judgment constitutes a violation of

Proposition 65 or other laws, ERC shall not be limited to enforcement of this Consent Judgment, but may seek in another action whatever fines, costs, penalties, or remedies as are provided by law for failure to comply with Proposition 65 or other laws.

17. ENTIRE AGREEMENT, AUTHORIZATION

- 17.1 This Consent Judgment contains the sole and entire agreement and understanding of the Parties with respect to the entire subject matter herein, and any and all prior discussions, negotiations, commitments, and understandings related hereto. No representations, oral or otherwise, express or implied, other than those contained herein have been made by any Party. No other agreements, oral or otherwise, unless specifically referred to herein, shall be deemed to exist or to bind any Party.
- 17.2 Each signatory to this Consent Judgment certifies that he or she is fully authorized by the Party he or she represents to stipulate to this Consent Judgment.

18. REQUEST FOR FINDINGS, APPROVAL OF SETTLEMENT AND ENTRY OF CONSENT JUDGMENT

This Consent Judgment has come before the Court upon the request of the Parties. The Parties request the Court to fully review this Consent Judgment and, being fully informed regarding the matters which are the subject of this action, to:

- (1) Find that the terms and provisions of this Consent Judgment represent a fair and equitable settlement of all matters raised by the allegations of the Complaint that the matter has been diligently prosecuted, and that the public interest is served by such settlement; and
- (2) Make the findings pursuant to California Health and Safety Code section 25249.7(f)(4), approve the Settlement, and approve this Consent Judgment.

IT IS SO STIPULATED:

Dated: 3/30/, 2017

ENVIRONMENTAL RESEARCH CENTER, INC.

By: The State of the Christ Police Directive D

Page 15 of 17

STIPULATED CONSENT JUDGMENT

Case No. RG17851569

1	Dated: March 31 , 2017	VITALAB CO., INC.	
2		By: Sharla Su	ු ුරුව
3		Sharla Swope, President	
4			
5	Dated: March 31, 2017	SONNE'S ORGANIC FO	ODS, INC
6	Dated. William, 2017	Δ	10 Q
7		Sharla Swope, President	<u>Ola</u>
8			
9			
10	Dated: March 31, 2017		
11		By: Sharla Swi	2 bg
12		Sharla Swope, President	
13			
14	Dated: March 31 , 2017	SPRINGREEN PRODUC	TS. INC.
15	paned penedicular	By: Sharla Swo	
16 17		By: Sharla Swope, President	<u>a</u>
8			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
		Page 16 of 17 TIPULATED CONSENT JUDGMENT	Case No. RG17851569
	5)	Trulated Cousent Jodgment	Case 140. NG1 /051303
I	1		

1			
2	APPROVED AS TO FORM:		
3	Dated: March 30, 2017 AQUA TERRA AERIS LAW GROUP		
4			
5	the E-		
6	Ву:		
7	Matthew C. Maclear Anthony M. Barnes		
8	Attorneys for Plaintiff Environmental Research Center, Inc.		
9			
10	Dated: March 31, 2017 EMORD & ASSOCIATES		
11	0 11 11		
12	By: A Peter A. Arhangelsky		
13	Attorney for Defendants Vitalab Co., Inc., Sonne's Organic Foods, Inc., V.E. Irons,		
14	Inc., and Springreen Products, Inc.		
15	ORDER AND JUDGMENT Based upon the Parties' Stipulation, and good cause appearing, this Consent Judgment is approved and Judgment is hereby entered according to its terms. IT IS SO ORDERED, ADJUDGED AND DECREED.		
16			
17			
18			
19			
20	Dated: 5 / 24 , 2017 Judge of the Superior Court		
21			
23			
24			
25			
26			
27			
28			
	Page 17 of 17		
	STIPULATED CONSENT JUDGMENT Case No. RG1785156		

,